Publication

This publication presents an analysis of drugs and diagnostics, focusing on ways in which incentives in the supply chain relationships protect - or fail to protect - drug efficacy. It examines incentives for actors to engage in countering drug resistance, and finds that pharmaceutical and large biotech companies have weak incentives to pay adequate attention to the impact of such resistance, as do private clinics and dispensers. The author suggests specific measures to enhance the capacity of drug regulatory authorities and recommends the creation of a global umbrella organization which sets the 'meta operating principles' for quality-accredited networks and ensures rational drug dispensation.